EMA approved biosimilars for the treatment of MSDs [18]
| Biosimilar name | Reference biologic* | Brand name | Indications |
|---|---|---|---|
| Abrilada | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Amgevita | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Amsparity | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Ardalicip | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Avsola | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Benepali | Etanercept | Enbrel | RA, PsA, AS, PsO |
| Ciptunec | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Cyltezo | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Erelzi | Etanercept | Enbrel | RA, PsA, AS, PsO |
| Eticovo | Etanercept | Enbrel | RA, PsA, AS, PsO |
| Flixabi | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Halimatoz | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Hadlima | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Hulio | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Hukyndra | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Hyrimoz | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Idacio | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Imraldi | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Inflectra | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Ixifi | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Kromeya | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Libmyris | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Mabura | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Nepexto | Etanercept | Enbrel | RA, PsA, AS, PsO |
| Pyzchiva | Ustekinumab | Stelara | PsA, CD, UC, PsO |
| Remsima | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Renflexis | Infliximab | Remicade | RA, PsA, AS, CD, UC, PsO |
| Simlandi | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Solymbic | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Steqeyma | Ustekinumab | Stelara | PsA, CD, UC, PsO |
| Tofidence | Tocilizumab | RoActemra | RA, SJIA, PJIA, COVID-19 |
| Trudexa | Adalimumab | Humira | RA, PsA, AS, CD, UC, PsO |
| Tyenne | Tocilizumab | RoActemra | RA, SJIA, PJIA, COVID-19 |
* The EMA does not use US-style suffixes to differentiate biosimilars from their reference biologic. AS: ankylosing spondylitis; CD: Crohn’s disease; EMA: European Medicines Agency; MSDs: musculoskeletal diseases; PJIA: polyarticular juvenile idiopathic arthritis; PsA: psoriatic arthritis; PsO: plaque psoriasis; RA: rheumatoid arthritis; SJIA: systemic juvenile idiopathic arthritis; UC: ulcerative colitis